



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 June 2023
EMA/281506/2023
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Jardiance empagliflozin

On 22 June 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Jardiance. The marketing authorisation holder for this medicinal product is Boehringer Ingelheim International GmbH.

The CHMP adopted a new indication for the treatment of chronic kidney disease. For information, the full indications for Jardiance will be as follows:²

Type 2 diabetes mellitus

Jardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance
- in addition to other medicinal products for the treatment of diabetes

Heart failure

Jardiance is indicated in adults for the treatment of symptomatic chronic heart failure.

Chronic kidney disease

Jardiance is indicated in adults for the treatment of chronic kidney disease.

Detailed recommendations for the use of this product will be described in the updated summary of product characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² New text in bold

